Effect	effect	O	O	O	O
of	of	O	O	O	O
direct	direct	O	O	O	O
intracoronary	intracoronary	O	O	O	O
administration	administration	O	O	O	O
of	of	O	O	O	O
methylergonovine	methylergonovine	O	O	OTHERS	I
in	in	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
and	and	O	O	O	O
without	without	O	O	O	O
variant	variant	O	DISEASE	OTHERS	I
angina	angina	O	DISEASE	OTHERS	I
.	.	O	O	O	O

The	the	O	O	O	O
effects	effects	O	O	O	O
of	of	O	O	O	O
intracoronary	intracoronary	O	O	O	O
administration	administration	O	O	O	O
of	of	O	O	O	O
methylergonovine	methylergonovine	O	O	OTHERS	I
were	were	O	O	O	O
studied	studied	O	O	O	O
in	in	O	O	O	O
21	21	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
variant	variant	O	DISEASE	OTHERS	I
angina	angina	O	DISEASE	OTHERS	I
and	and	O	O	O	O
22	22	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
atypical	atypical	O	O	O	O
chest	chest	O	DISEASE	OTHERS	I
pain	pain	O	DISEASE	OTHERS	I
and	and	O	O	O	O
in	in	O	O	O	O
others	others	O	O	O	O
without	without	O	O	O	O
angina	angina	O	DISEASE	OTHERS	I
pectoris	pectoris	O	DISEASE	OTHERS	I
(	(	O	O	O	O
control	control	O	O	O	O
group	group	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

Methylergonovine	methylergonovine	O	O	OTHERS	I
was	was	O	O	O	O
administered	administered	O	O	O	O
continuously	continuously	O	O	O	O
at	at	O	O	O	O
a	a	O	O	O	O
rate	rate	O	O	O	O
of	of	O	O	O	O
10	10	O	O	O	O
micrograms/min	micrograms/min	O	O	O	O
up	up	O	O	O	O
to	to	O	O	O	O
50	50	O	O	O	O
micrograms	micrograms	O	O	O	O
.	.	O	O	O	O

In	in	O	O	O	O
all	all	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
variant	variant	O	DISEASE	OTHERS	I
angina	angina	O	DISEASE	OTHERS	I
,	,	O	O	O	O
coronary	coronary	O	DISEASE	OTHERS	I
spasm	spasm	O	DISEASE	OTHERS	I
was	was	O	O	O	O
provoked	provoked	O	O	O	O
at	at	O	O	O	O
a	a	O	O	O	O
mean	mean	O	O	O	O
dose	dose	O	O	O	O
of	of	O	O	O	O
28	28	O	O	O	O
+	+	O	O	O	O
/-	/-	O	O	O	O
13	13	O	O	O	O
micrograms	micrograms	O	O	O	O
(	(	O	O	O	O
mean	mean	O	O	O	O
+	+	O	O	O	O
/-	/-	O	O	O	O
SD	sd	O	O	OTHERS	I
)	)	O	O	O	O
.	.	O	O	O	O

In	in	O	O	O	O
the	the	O	O	O	O
control	control	O	O	O	O
group	group	O	O	O	O
neither	neither	O	O	O	O
ischemic	ischemic	O	O	OTHERS	I
ST	st	O	O	O	O
change	change	O	O	O	O
nor	nor	O	O	O	O
localized	localized	O	O	O	O
spasm	spasm	O	DISEASE	OTHERS	I
occurred	occurred	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
basal	basal	O	O	O	O
tone	tone	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
right	right	O	O	O	O
coronary	coronary	O	O	O	O
artery	artery	O	O	O	O
was	was	O	O	O	O
significantly	significantly	O	O	O	O
lower	lower	O	O	O	O
than	than	O	O	O	O
that	that	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
left	left	O	O	O	O
coronary	coronary	O	O	O	O
artery	artery	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
percentage	percentage	O	O	O	O
of	of	O	O	O	O
vasoconstriction	vasoconstriction	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
right	right	O	O	O	O
coronary	coronary	O	O	O	O
artery	artery	O	O	O	O
was	was	O	O	O	O
significantly	significantly	O	O	O	O
higher	higher	O	O	O	O
than	than	O	O	O	O
that	that	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
left	left	O	O	O	O
coronary	coronary	O	O	O	O
artery	artery	O	O	O	O
.	.	O	O	O	O

These	these	O	O	O	O
results	results	O	O	O	O
suggest	suggest	O	O	O	O
that	that	O	O	O	O
spasm	spasm	O	DISEASE	OTHERS	I
provocation	provocation	O	O	O	O
tests	tests	O	O	O	O
,	,	O	O	O	O
which	which	O	O	O	O
use	use	O	O	O	O
an	an	O	O	O	O
intracoronary	intracoronary	O	O	O	O
injection	injection	O	O	O	O
of	of	O	O	O	O
a	a	O	O	O	O
relatively	relatively	O	O	O	O
low	low	O	O	O	O
dose	dose	O	O	O	O
of	of	O	O	O	O
methylergonovine	methylergonovine	O	O	OTHERS	I
,	,	O	O	O	O
have	have	O	O	O	O
a	a	O	O	O	O
high	high	O	O	O	O
sensitivity	sensitivity	O	O	O	O
in	in	O	O	O	O
variant	variant	O	DISEASE	OTHERS	I
angina	angina	O	DISEASE	OTHERS	I
and	and	O	O	O	O
the	the	O	O	O	O
vasoreactivity	vasoreactivity	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
right	right	O	O	O	O
coronary	coronary	O	O	O	O
artery	artery	O	O	O	O
may	may	O	O	O	O
be	be	O	O	O	O
greater	greater	O	O	O	O
than	than	O	O	O	O
that	that	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
other	other	O	O	O	O
coronary	coronary	O	O	O	O
arteries	arteries	O	O	O	O
.	.	O	O	O	O

